Tablet quickly disintegrating in the oral cavity and method for producing the same

1. A tablet, which is rapidly disintegrated in an oral cavity, comprising (a) an active ingredient selected from the group consisting of acetaminophen, ibuprofen, indomethacin, ethenzamide, droxidopa, levodopa, amoxicillin, cefalexin, erythromycin, and clarithromycin in not less than 25% of the total weight, (b) mannitol, (c) corn-derived pregelatinized starch, and (d) at least one disintegrant selected from the group consisting of cornstarch, hydroxypropylstarch, carmellose and crospovidone, wherein the tablet is obtained by compression molding of a mixture comprising a granule obtainable by granulating a powder comprising the active ingredient with a binding solution comprising mannitol and corn-derived pregelatinized starch, and at least one disintegrant.

2. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , further having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm 2 or more, which is obtained by compression molding of a mixture of a granule produced by granulating a powder comprising the active ingredient with a binding solution comprising mannitol and corn-derived pregelatinized starch, and at least one disintegrant selected from the group consisting of cornstarch, hydroxypropylstarch, carmellose and crospovidone.

3. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , wherein the absolute hardness is 2.0 N/mm 2 or more.

4. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , wherein the disintegrant is cornstarch or hydroxypropylstarch.

5. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , wherein the powder comprises the active ingredient and mannitol.

6. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , comprising the active ingredient in not less than 40% of the total weight.

7. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 6 , comprising the active ingredient in 40%-70% of the total weight.

8. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , wherein the active ingredient is droxidopa or levodopa.

9. A method of producing a tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , which method comprises the following steps:

(1) a step of granulating a powder comprising the active ingredient with a binding solution comprising mannitol and corn-derived pregelatinized starch to produce a granule comprising the active ingredient;

(2) a step of mixing the granule comprising the active ingredient obtained in (1) with at least one disintegrant selected from the group consisting of cornstarch, hydroxypropylstarch, carmellose and crospovidone; and

(3) a step of compression molding a pre-tableting composition comprising the mixture obtained in (2).

10. A method of producing the tablet, which is rapidly disintegrated in an oral cavity, according to claim 4 , which method comprises the following steps:

(1) a step of granulating a powder comprising the active ingredient with a binding solution comprising mannitol and corn-derived pregelatinized starch to produce a granule comprising the active ingredient;

(2) a step of mixing the granule comprising the active ingredient obtained in (1) with a disintegrant which is cornstarch or hydroxypropylstarch; and

(3) a step of compression molding of the mixture obtained in (2).

11. The method according to claim 9 , wherein a disintegration time of the tablet, which is rapidly disintegrated in an oral cavity, is 40 seconds or less, and an absolute hardness thereof is 1.8 N/mm 2 or more.

12. The method according to claim 9 , comprising a step of compression molding by an external lubrication method.

13. The method according to claim 9 , wherein the absolute hardness of the tablet, which is rapidly disintegrated in an oral cavity, is 2.0 N/mm 2 or more.

14. The method according to claim 9 , wherein the active ingredient is droxidopa or levodopa.

15. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , wherein the granule does not contain a disintegrant selected from the group consisting of cornstarch, hydroxypropylstarch, carmellose, and crospovidone.

16. The method according to claim 9 , wherein the granule does not contain a disintegrant selected from the group consisting of cornstarch, hydroxypropylstarch, carmellose, and crospovidone.

17. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , which is obtained by the following steps:

(1) a step of granulating a powder comprising the active ingredient with a binding solution comprising mannitol and corn-derived pregelatinized starch to produce a granule comprising the active ingredient;

(2) a step of mixing the granule comprising the active ingredient obtained in (1) with at least one disintegrant selected from the group consisting of cornstarch, hydroxypropylstarch, carmellose, and crospovidone; and

(3) a step of compression molding a pre-tableting composition comprising the mixture obtained in (2).

18. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 1 , wherein the active ingredient is droxidopa.

19. The tablet, which is rapidly disintegrated in an oral cavity, according to claim 7 , wherein the active ingredient is droxidopa.

20. The method according to claim 9 , wherein the active ingredient is droxidopa.